PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA

Abstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into...

Full description

Saved in:
Bibliographic Details
Main Authors: G. I. Litvinenko, A. V. Shurlygina, V. S. Shirinsky, V. M. Nepomnjаshih, I. V. Shirinsky, V. A. Trufakin
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2014-07-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/613
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849401452850577408
author G. I. Litvinenko
A. V. Shurlygina
V. S. Shirinsky
V. M. Nepomnjаshih
I. V. Shirinsky
V. A. Trufakin
author_facet G. I. Litvinenko
A. V. Shurlygina
V. S. Shirinsky
V. M. Nepomnjаshih
I. V. Shirinsky
V. A. Trufakin
author_sort G. I. Litvinenko
collection DOAJ
description Abstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into the study. Melatonin (Melaxen, Unifarm, USA) was administered as a single daily dose of 0.003 g, at 21.00, accompanied by a standard therapy in twenty BA patients for 21 days. We determined contents and functional properties of Т- and B-lymphocytes, mononuclear phagocytes, IgE, IL-4, IFNγ levels, as well as melatonin concentrations in blood serum in the morning and evening time. When included into BA treatment protocol, melatonin proved to cause partial restoration of circadian rhythm for Tand B cell subpopulations, mononuclear phagocytes, cytokine production, due to its chronotropic and immunomodulating activity. This effect is associated with a more pronounced clinical effect, thus presuming reversibility of desynchronosis state.
format Article
id doaj-art-0d2a5554b86e4c9e97ffd35dd4c63c09
institution Kabale University
issn 1563-0625
2313-741X
language Russian
publishDate 2014-07-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj-art-0d2a5554b86e4c9e97ffd35dd4c63c092025-08-20T03:37:46ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-0114653354010.15789/1563-0625-2012-6-533-540610PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMAG. I. Litvinenko0A. V. Shurlygina1V. S. Shirinsky2V. M. Nepomnjаshih3I. V. Shirinsky4V. A. Trufakin5ФГБУ «Научно-исследовательский институт клинической и экспериментальной лимфологии» СО РАМН, г. НовосибирскФГБУ «Научно-исследовательский институт клинической и экспериментальной лимфологии» СО РАМН, г. НовосибирскФГБУ «Научно-исследовательский институт клинической иммунологии» СО РАМН, г. НовосибирскФГБУ «Научно-исследовательский институт клинической иммунологии» СО РАМН, г. НовосибирскФГБУ «Научно-исследовательский институт клинической иммунологии» СО РАМН, г. НовосибирскФГБУ «Научно-исследовательский институт физиологии» СО РАМН, г. НовосибирскAbstract. Present study dealt with efficiency of melatonin implementation in a combination therapeutic schedule of bronchial asthma (BA). A group of 248 patients with atopic, or mixed clinical forms of BA being in exacerbation, or medication remission state, and 36 healthy donors were included into the study. Melatonin (Melaxen, Unifarm, USA) was administered as a single daily dose of 0.003 g, at 21.00, accompanied by a standard therapy in twenty BA patients for 21 days. We determined contents and functional properties of Т- and B-lymphocytes, mononuclear phagocytes, IgE, IL-4, IFNγ levels, as well as melatonin concentrations in blood serum in the morning and evening time. When included into BA treatment protocol, melatonin proved to cause partial restoration of circadian rhythm for Tand B cell subpopulations, mononuclear phagocytes, cytokine production, due to its chronotropic and immunomodulating activity. This effect is associated with a more pronounced clinical effect, thus presuming reversibility of desynchronosis state.https://www.mimmun.ru/mimmun/article/view/613melatoninimmune statusbronchial asthma
spellingShingle G. I. Litvinenko
A. V. Shurlygina
V. S. Shirinsky
V. M. Nepomnjаshih
I. V. Shirinsky
V. A. Trufakin
PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
Медицинская иммунология
melatonin
immune status
bronchial asthma
title PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_full PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_fullStr PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_full_unstemmed PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_short PATHOGENETIC JUSTIFICATION AND EFFICIENCY OF MELATONIN APPLICATION IN PATIENTS WITH BRONCHIAL ASTHMA
title_sort pathogenetic justification and efficiency of melatonin application in patients with bronchial asthma
topic melatonin
immune status
bronchial asthma
url https://www.mimmun.ru/mimmun/article/view/613
work_keys_str_mv AT gilitvinenko pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
AT avshurlygina pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
AT vsshirinsky pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
AT vmnepomnjashih pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
AT ivshirinsky pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma
AT vatrufakin pathogeneticjustificationandefficiencyofmelatoninapplicationinpatientswithbronchialasthma